The Role of Isocitrate Lyase (ICL1) in the Metabolic Adaptation of

Candida albicans Biofilms by Ishola, Oluwaseun Ayodeji et al.
Jundishapur J Microbiol. 2016 September; 9(9):e38031.
Published online 2016 August 30.
doi: 10.5812/jjm.38031.
Research Article
The Role of Isocitrate Lyase (ICL1) in the Metabolic Adaptation of
Candida albicans Biofilms
Oluwaseun Ayodeji Ishola,1 Seng Yeat Ting,1 Yasser M Tabana,1 Mowaffaq Adam Ahmed,1 Muhammad
Amir Yunus,1 Rafeezul Mohamed,2 Leslie Thian Lung Than,3 and Doblin Sandai1,*
1Infectomics Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Malaysia
2Regenerative Medicine Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Malaysia
3Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia
*Corresponding author: Doblin Sandai, Infectomics Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Malaysia. Tel: +60-45622386, Fax: +60-194951073,
E-mail: doblin@usm.my, drdoblinamdiusm@gmail.com
Received 2016 March 24; Revised 2016 August 14; Accepted 2016 August 19.
Abstract
Background: A major characteristic of Candida biofilm cells that differentiates them from free-floating cells is their high tolerance
to antifungal drugs. This high resistance is attributed to particular biofilm properties, including the accumulation of extrapoly-
meric substances, morphogenetic switching, and metabolic flexibility.
Objectives: This study evaluated the roles of metabolic processes (in particular the glyoxylate cycle) on biofilm formation, antifun-
gal drug resistance, morphology, and cell wall components.
Methods: Growth, adhesion, biofilm formation, and cell wall carbohydrate composition were quantified for isogenic Candida albi-
cans ICL1/ICL1, ICL1/icl1, and icl1/icl1 strains. The morphology and topography of these strains were compared by light microscopy and
scanning electron microscopy. FKS1 (glucan synthase), ERG11 (14-α-demethylase), and CDR2 (eﬄux pump) mRNA levels were quanti-
fied using qRT-PCR.
Results: The ICL1/icl1 and icl1/icl1 strains formed similar biofilms and exhibited analogous drug-tolerance levels to the control
ICL1/ICL1 strains. Furthermore, the drug sequestration ability of β-1, 3-glucan, a major carbohydrate component of the extracel-
lular matrix, was not impaired. However, the inactivation of ICL1 did impair morphogenesis. ICL1 deletion also had a considerable
effect on the expression of the FKS1, ERG11, and CDR2 genes. FKS1 and ERG11 were upregulated in ICL1/icl1 and icl1/icl1 cells through-
out the biofilm developmental stages, and CDR2 was upregulated at the early phase. However, their expression was downregulated
compared to the control ICL1/ICL1 strain.
Conclusions: We conclude that the glyoxylate cycle is not a specific determinant of biofilm drug resistance.
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1. Background
Fungal pathogens are gaining increasing attention as
infection rates increase due to advances in healthcare and
rising numbers of susceptible immunocompromised pa-
tients (1, 2), and their major impact on human health is be-
coming better appreciated. Despite advancements in the
management of hospital-acquired infections, Candida al-
bicans, a commensal organism that helps maintain micro-
biota normalcy, is the fourth most common isolated noso-
comial bloodstream pathogen, after Staphylococcus aureus,
accounting for approximately 80% of candidemia cases
with a 40% fatality rate (3-9). These microbes exist pre-
dominantly as attached aggregated communities in na-
ture, forming an irreversible assemblage that is strongly
influenced by the growth medium, the attachment sur-
faces, and the environment. Microcolonies of cells are shel-
tered in self-secreted polymeric substances and communi-
cate via quorum sensing (10-12).
Biofilm growth is a unique virulence trait and defense
mechanism of C. albicans that is associated with infec-
tious diseases and the clinical use of implanted medical
devices, such as central catheters and intracardiac pros-
thetic valves. Candida albicans causes life-threatening con-
ditions, such as urinary tract infection and endocarditis,
with a mortality rate as high as 30% (10, 13, 14). Despite
treatment, such an infection may re-establish itself. Sessile
cells are phenotypically and genetically different from free-
floating cells. A characteristic attribute of biofilms, unlike
planktonics, is resistance to antifungal agents, particularly
azole, polyenes, and recently, echinocandins. Candida albi-
cans sessile cell resistivity is always expressed, irrespective
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of definite phenotypic variation and the expression of spe-
cific drug-resistance genes, entailing complex multicellu-
lar processes (11, 15, 16). Due to this property, in most clin-
ical cases, replacement of the infected devices is the only
treatment option (13, 17, 18). Thus, it is imperative to de-
velop effective strategies for control. Recent research has
begun to shed light on how attached microbial communi-
ties develop resistance to antifungal agents, proposing var-
ious involved mechanisms (13, 14). This peculiar phenotype
has been reported by previous studies to be a multifacto-
rial phenomenon not regulated by a singular mechanism,
which was confirmed by this study.
2. Objectives
In this study, we examined whether C. albicans biofilm
development depends on the glyoxylate pathway since this
is essential for the assimilation of many alternative car-
bon sources in the absence of glucose, and we investigated
whether this pathway contributes to the high tolerance of
biofilm cells to antifungal drug therapy. In addition, we
examined whether a correlation exists between cell carbo-




Candida albicans wildtype strain ICL1/ICL1, heterozy-
gous mutant ICL1/icl1, and homozygous mutant icl1/icl1
were obtained (Table 1). Strains were stored in 15% (vol/vol)
glycerol at -80°C and routinely maintained on YPD (1% yeast
extract, 2% peptone, and 2% dextrose; Sigma-Aldrich, USA)
and YPL media (1% yeast extract, 2% peptone, and 2% lac-
tate; (Sigma-Aldrich, USA) prior to the experiments.
Table 1. Candida albicans Strains Used in This Study
Strain Genotype/Description Source, (19)
CA1395 (ICL1/ICL1) RM1000: ura3∆:
λimm434/ura3∆: λimm434,
his1∆: hisG/his1∆: hisG, ICL1/ICL1
Barelle et al., 2006.
CA 510 (ICL1/icl1) RM1000:ura3:λimm434/ura3∆∆imm434his1:
hisG/his1∆: hisG; icl1:
loxP-HIS1loxP/ICL1
Barelle et al., 2006
CA 517 (icl1/icl1) RM1000icl1:
loxP-HIS1-lox/icl1:loxp-URA3-loxP.
Barelle et al., 2006
3.2. Biofilm Formation
Biofilm cultivation of the strains was performed using
the silicone elastomer protocol in 6-well plates and the 96-
well plate method (20, 21) with slight modification. Strains
were propagated in YPD, YPL (Paisley, UK), and RPMI 1640
media inoculated with single colony cells from overnight-
grown stock culture, in an orbital shaker at 200 rpm and
35°C. The overnight grown wildtype, single-knockout, and
double-knockout C. albicans cells were harvested by cen-
trifuging at 3,000 rpm for 5 minutes at 4°C (3×). The
cells were standardized using the spectrophotometer to
OD600 of 0.1. Next, 100 µL of the standardized inoculum
was pipetted into the selected wells and incubated for var-
ious time intervals, depicting their developmental growth
phases (6, 24, and 48 hours) at 37°C. This experiment was
performed in 2 - 4 replicates.
Biofilm cultivation on cellulose filter paper (15 mm in
diameter, 0.2 µm pore size) was carried out using flat-
bottomed 6-well plates. Strains were inoculated into 100
mL of YPL, YPD, and RPMI 1640 supplemented broths and
incubated overnight in an orbital shaker at 35°C and 200
rpm. After the centrifugation of the previously grown pri-
mary culture, the cell pellets were resuspended in sterile
10 mL 0.15 M PBS and cell density was standardized to 1
× 107 CFU/mL. Next, 2 mL of each inoculum was added
to 6-well plates containing sterilized 15 mm filter mem-
branes, and incubated for 90 minutes at 37°C for adhesion
of cells to the membranes, without shaking. After the ad-
hesion phase, the medium was carefully aspirated and the
membranes were gently washed in 2 mL sterile 0.15 MPBS
twice to remove non-adherent cells. The membranes were
carefully transferred with a sterile forceps into new 6-well
plates containing 2 mL of YPD and YPL and supplemented
with RPMI-1640. The plates were incubated for different
time intervals (6, 24, and 48 hours) at 37°C, representing
the early, intermediate, and mature phases, respectively, of
biofilm formation.
3.3. MTT Reduction Assay
A colorimetric MTT reduction assay was performed as
described by Hawser and Douglas in 1995 (22). Stock solu-
tion (0.5%, 5 mg/mL-1) was prepared by dissolving 5 mg of
MTT salt into 1 mL of sterile PBS. Working solution was pre-
pared by diluting the stock 1: 10 (V/V).
3.4. Antifungal Susceptibility
For antifungal susceptibility testing of sessile cells,
biofilms that formed on the microtiter plates at the various
time intervals (6, 24, and 48 hours) were challenged with
antifungal drugs. The media were aspirated off and gently
washed twice with sterile PBS, then 100 µL of YPD and YPL
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broth and RPMI 1640 medium containing serially diluted
concentrations of antifungals (fluconazole 256 µg/mL and
amphotericin B 16 µg/mL) was added and the plates were
incubated for another 24 hours at 37°C. The MTT reduction
assay at 405 nm was performed as described (22). The ex-
periment was performed in 2 - 4 replicates.
3.5. Biofilm Compound Light Microscopy
The developmental stages were examined using a com-
pound light. At different time intervals, the biofilms grown
in lactate medium were repeatedly washed with PBS and
viewed at 20×magnification.
3.6. Biofilm Scanning Electron Microscopy (SEM)
The biofilms were fixed using McDowell-Trump fixa-
tive on cellulose filter paper. The membranes were serially
dehydrated by ethanol washes and immersed in hexam-
ethyldisilazane (HMDS) (Sigma-Aldrich, USA). After drying,
the dehydrated substrates were mounted on the stub. The
studs were sputter-coated with gold and palladium (Au/Pd
60/40).
3.7. Cell Wall Polysaccharide Isolation and Composition
Sessile cell soluble extracellular polysaccharides, in-
soluble extracellular polysaccharides, and intracellular
polysaccharides were extracted using 1 M NaOH. Into all
of the tubes containing sycamore extracellular polysaccha-
rides (SEPS), insoluble extracellular polysaccharides (IEPS),
and intracellular polysaccharides (IPS), 5 mL of absolute
ethanol was added, then the tubes were incubated at -
20°C for 30 - 60 minutes. All tubes were centrifuged and
washed twice with pre-chilled 75% ethanol. The carbohy-
drate content of each fraction was measured using the
phenol-sulfuric acid method, and the results were normal-
ized to a standard curve.
3.8. Beta-1, 3-Glucan Measurement
The matrix glucan was measured using a limulus
lysate-based assay as previously described by Nett et al. (14).
Biofilms were dislodged and samples were sonicated for 5
minutes at 7 W in PBS, then centrifuged 3× at 10,000 rpm
for 5 minutes at 4°C to separate the cells from the solu-
ble extracellular polysaccharide with the matrix material.
Beta-1, 3-glucan was measured using the Glucatell (1, 3)-β-D-
glucan detection reagent kit.
3.9. RNA Isolation and RT-PCR Expression Analysis
At each developmental stage, the biofilms were washed
3×with PBS. TRI reagent was used for RNA extraction. Pre-
chilled chloroform was added for separation, and 500 µL
of pre-chilled isopropanol was added to the clear aque-
ous upper part for precipitation. The supernatant was
removed and the resulting pellets were washed with 75%
ethanol and resuspended in 40 µL of dH2O. Complemen-
tary DNA was generated from the RNA using a Tetro cDNA
synthesis kit according to the manufacturer’s instructions.
Expression levels of the desired genes were quantified us-
ing light-cycle 480 SYBR green kits according to the manu-
facturer’s instructions, with a small amount of optimiza-
tion. Reactions were run at denaturation for 15 seconds
and at melting temperature for 15 seconds, with an exten-
sion time of 30 seconds for approximately 40 cycles (Table
2) (23).
Table 2. Primers Used for qRT-PCR
















Analyses were performed using SPSS 17.0 for Windows.
One-way ANOVA was performed to analyze the differences
among multiple means. According to the tests of homo-
geneity of variances, Bonferroni-Dunn was carried out for
post-hoc multiple comparisons. P values of < 0.05 were
considered statistically significant.
4. Results
4.1. Biofilm Formation is Independent of Isocitrate Lyase
The icl1/icl1 mutants formed biofilms, as revealed by
MTT quantification, at each developmental stage. Interest-
ingly, ICL1/icl1 and icl1/icl1 cells were metabolically active at
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a similar level to the wildtype cells in the presence and ab-
sence of glucose. Figure 2A - 2C depict a significantly (P
< 0.05) higher degree of formation in glucose and lactate
media in the wildtype and icl1/icl1 strains than in ICL1/icl1.
However, metabolic activity increased with maturation in
all strains. There was no significant difference among the
three strains on RPMI 1640. At maturity, the strains’ growth
displayed no obvious differences on YPL and YPD. This re-
sult indicates that ICL1 is not essential for growth under
these conditions.
4.2. Resistance Phenotype is Independent of Isocitrate Lyase
We investigated ICL’s impact on C. albicans biofilm
resistivity. Biofilms at each developmental phase on a
non-carbohydrate medium (lactate) were treated with 256
µg/mL of fluconazole and 16 µg/mL of amphotericin B
based on SMIC50%. Figure 3A - 3C show that the reference,
ICL1/icl1, and icl1/icl1 strains exhibited high resistance to
fluconazole at the 256 µg/mL concentration at all stages
(as well as in the YPD and RPMI media; data not shown).
Growth was characterized by high metabolic activity that
did not deviate significantly from untreated biofilms. As
seen in Figure 3B - 3C, a 20% inhibitory effect was con-
served with 16 µg/mL amphotericin B on ICL1/icl1 and
icl1/icl1 biofilms at 6 hours. However, resistance built up at
the intermediate and mature phases, as seen in Figure 3B -
3C. In addition, resistance increased with metabolic activ-
ity regardless of the supporting medium and the in vitro
materials used. This result indicates that the glyoxylate cy-
cle is not essential for resistance to these antifungal drugs.
4.3. Biofilms Grow in Three Developmental Stages
Our results confirmed that biofilm development pro-
gresses in three distinct stages. The early phase (Figure
4A - 4C) showed free-floating cells attached to the substra-
tum and to each other in microcolonies. The intermedi-
ate phase (Figure 4D - 4F) shows active replication, evident
through increased numbers of microcolonies, with hetero-
geneous communities consisting of hyphae and pseudo-
hyphae in the wildtype cells (Figure 4D). Filamentous mor-
phogenesis was absent in the mutant biofilms (Figure 4E -
4I).
4.4. Isocitrate Lyase (ICL) Alters Morphogenesis
In an attempt to visualize the role of ICL on biofilm
structural organization and morphology during chal-
lenges with antifungal drugs, mature biofilms of the refer-
ence and reconstructed mutants on cellulose membranes
were treated with 256 µg/mL of fluconazole, then exam-
ined under SEM and compared to untreated biofilms.
Selected concentrations were based on generated sus-
ceptibility testing data. The reference strain-treated
biofilm (Figure 5A) conformed to previous descriptions
[33]. This community presented a highly heterogeneous
assemblage, with visible pseudohyphae, hyphae, and blas-
tospores encased within the ECM and divided into two
distinct layers. Blastospores were more concentrated and
tightly packed at the basal region, while the upper region
consisted of pseudohyphae and true hyphae networks. Un-
treated wildtype biofilms (Figure 5B) exhibited substan-
tially less hyphae growth, consisting mostly of budding,
densely packed, clustered yeast cells. Hyphae growth was
incapacitated and defective in the reconstructed mutants,
with no visible bilayer in either the treated or the un-
treated biofilms. The treated ICL1/icl1 strain seen in Fig-
ure 5C showed resistance, as indicated by the steadiness
of metabolic activity and the detectable cluster of yeast
cells in the basal region. The untreated biofilm seen in Fig-
ure 5D was characterized by a mass cluster of viable cells
with defective hyphae growth. The icl1/icl1 strain (Figure
5E) exhibited the same basal composition as ICL1/icl1, but
with smaller and denser adhered, mature, and budding
blastospores. The generated images suggest that ICL1 influ-
ences morphogenesis under these conditions.
4.5. ECM β-1, 3-Glucan is Dependent on Cell Wall Polysaccha-
rides
We designed a hypothesis to answer whether sessile
cells generate glucan using alternative generated hexoses
in the absence of the glyoxylate pathway in relative pro-
portion to when glyoxylate is present. Also, we further ex-
ploited the extent of glucan defenses against treatment at
each developmental stage. Table 3 reveals that the cell wall
carbohydrates of treated and untreated strains increased
with time. Compared to the wildtype cells, hexose accu-
mulation in untreated and treated icl1/icl1 and ICL1/icl1 was
not impaired despite the absence of ICL. These data indi-
cate that hexoses were synthesized through other active
pathways. Synthesis was more amplified in treated than in
untreated biofilms, and the increment was proportional to
time.
Sequestration activity through matrix β-1, 3-glucan en-
coded by the FKS1 gene mediates tolerance to azole drugs
[40, 41]. To determine theβ-1, 3-glucan concentration in the
matrix, C. albicans wildtype, ICL1/icl1, and icl1/icl1 biofilms
on YPL medium were measured using a Glucatell (1, 3)-β-D-
glucan detection reagent kit based on limulus lysate. Fig-
ure 6A - 6B show that the increase was significantly higher
in wildtype and icl1//icl1 compared to ICL1/icl1 at all stages.
At the mature stages, ICL1/ICL1 showed a greater rate than
the mutant strain, and the icl1/icl1 glucan level was moder-
ately higher than that of ICL1/icl1. After treatment, as de-
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Figure 1. Inverted Microscopy Images of C. albicans Biofilms at Different Growth Stages on RPMI 1640 Medium
These images depict biofilm formation on a polystyrene surface under static conditions through the three developmental phases. A, Growing predominantly as yeast cells,
attachment of the cells to the potential growth material and to each other was observed; B, metabolic activity increased with cellular density in correlation with the duration
of cultivation. This image shows cells at the maturation phase; C, Microcommunities became heterogeneous and clustered. Apparent production and visible accumulation
of slime extracellular matrix (ECM) enclosing the sessile yeast and filamentous cells, which increased with maturity, was observed.
picted in Figure 6B, glucan levels were significantly higher
(P > 0.05) in the wildtype at 6 and 24 hours. These results
indicate that the concentrations were significantly higher
in treated than in untreated biofilms. All of the strains
synthesized β-1, 3-glucan at different rates. A direct rela-
tionship was observed between hexose and β-1, 3-glucan
because as carbohydrate increased, glucan also increased
in the matrix, confirming that concentration in the ECM is
dependent on the amount of hexose present. We can say
that modulation of ICL did not lower or halt synthesis be-
cause hexoses were produced independently. Evidence of
resistance, tolerance with maturation, resistance to drugs,
and the synthesis of glucan signifies glucan’s major impact
on the phenotype. This research showed that metabolism
through the preferred alternative glyoxylate pathway is
not a specific regulator of the biofilm resistance pheno-
type.
4.6. Transcript Profile of Associated Resistance Genes Regulated
by Isocitrate Lyase
We investigated the extent of ICL’s regulatory role on
FKSI, ERG11, and CDR2 at the mRNA expression level using
real-time qPCR. ACT1 was used as a housekeeping gene. The
expression profiles of ICL1/icl1 and icl1//icl1 were compared
to that of the wildtype strain. Figure 7A shows that the ex-
pression level of FKSI in the mutants was downregulated
compared to the wildtype. FKS1 transcript levels were rel-
atively high at the intermediate phase in the mutants, al-
though no fold to the wildtype was suggested, and expres-
sion decreased at maturity. Expression of ERG11 in icl1/icl1 re-
gressed over time, unlike that of ICL1/icl1, which increased
at the intermediate stage and regressed at maturity (Fig-
ure 7B). The drug eﬄux-pump level was also reduced with
maturation. The ICL1/icl1CDR2 level was higher than that of
Table 3. Comparison of Carbohydrate Concentrations of Biofilm Sessile Cell Walls















hours 49.4± 0.0 49.3± 0.6 +
hours 97.0± 0.0 98.0± 0.1 +








hours 26.0± 0.3 31.03± 1.0 +
hours 22.5± 0.6 65.1± 0.2 +








hours 19.6± 0.0 23.3± 0.6 +
hours 54.0± 0.0 151.0± 0.0 +
hours 46.0± 0.0 149± 0.6 +
the wildtype at the early phase and decreased to reference
levels at maturity. Overall, the transcript levels of the stud-
ied genes were downregulated to the wildtype, as shown
in Figure 7C. Therefore, our data show that ICL exerts a sub-
stantial regulatory effect on FKS1, ERG11, and CDR2 expres-
sion.
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Figure 2. A, The chart represents the average metabolic activity OD of C. albicans wildtype biofilms on YPL, YPD, and RPMI 1640 media, measured with the MTT assay at each
developmental stage (early, intermediate, and maturation). The results are representative of three independent experiments. Absorbance is plotted against growth intervals
(time); B, Heterozygous CaICL1/icl1 mutant biofilm on YPL, YPD, and RPMI 1640 media. Formation at early, intermediate, and maturation stages. The results are representative
of three independent experiments. Absorbance is plotted against growth intervals (time). Independent experiments were performed in triplicate; C, Homozygous CaIcl1/icl1
mutant biofilm on YPL, YPD, and RPMI 1640 media. Formation is shown at the early, intermediate, and maturation stages. The results are representative of three independent
experiments. Absorbance is plotted against growth intervals (time). Independent experiments were performed in triplicate.
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Figure 3. A, C. albicans wildtype susceptibility testing with fluconazole 128 µg/mL and amphotericin B 16 µg/mL on lactate-containing medium. ANOVA was carried out for
the statistical analysis to calculate the significant difference at each developmental level; B, Heterozygous CaICL1/icl1 mutant susceptibility testing with fluconazole 128µg/mL
and amphotericin B 16µg/mL on lactate-containing medium. ANOVA was carried out for the statistical analysis to calculate the significant difference at each developmental
level. Independent experiments were performed in triplicate.
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Figure 4. Developmental Stages of Biofilms
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Figure 5. SEM images of reference and knockout strain biofilms at maturity, before and after treatment. Biofilms were cultured for 48 hours at 37°C under static conditions
in YPL medium and visualized at 500×magnification. A, Treated wildtype ICL1/ICL1; B, untreated wildtype ICL1/ICL1; C, treated ICL1/icl1; D, untreated ICL1/icl1; E, treated icl1/icl1,
and F, untreated icl1/icl1. Images have been reconstructed to permit clear viewing.
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Figure 6. A, Quantification of β-1, 3-glucan present in the ECM of wildtype and mutant biofilms not treated with fluconazole at the early, intermediate, and mature phases,
respectively; B, Quantification of β-1, 3-glucan present in the ECM of the wildtype and mutant biofilms treated with 128 µg/mL fluconazole at the early, intermediate, and
mature phases, respectively.
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Figure7. A, Comparative Relative Transcriptional Expression of FKS1; Results were normalized to the internal control CaACT1; B, Comparative relative transcriptional expression
of ERG11. Results were normalized to the housekeeping gene CaACT1; C, Comparative relative transcriptional expression of CDR2. Results were normalized to the internal control
CaACT1.
Jundishapur J Microbiol. 2016; 9(9):e38031. 11
Ishola OA et al.
5. Discussion
Metabolic flexibility aids C. albicans in establishing in-
fections (19, 24, 25). We examined the possible roles of
ICL1, a major glyoxylate-synthesizing enzyme, in the dis-
tinctive traits of biofilms. Biofilm formation by ICL1/icl1
and icl1//icl1 showed a partial impact of ICL, as metabolic
activity remained high. The continual growth of ICL1 mu-
tants on non-fatty-acid compounds showed that glyoxy-
late is not the sole pathway capable of synthesizing C4
molecules for gluconeogenesis, suggesting the presence of
similar derivatives and other catabolic pathways. The gly-
oxylate cycle is preferred because it consumes less energy;
however, it can be bypassed in the presence of glucose, far-
nesol, lactate, malic acid, and succinic acid. Moreover, glu-
cose and fatty acids are more energetically favorable and
thus their presence represses lactate assimilation (19, 26).
Lactate, malic acid, and succinic acid derived from
pyruvate can be oxidized to oxaloacetate through the pyru-
vate dehydrogenase pathway. This supports the observa-
tion that ICL1/icl1 and icl1/icl1 are able to form extensive
biofilms in lactate-containing media. The low assimilation
observed in ICL1/icl1 (Figure 2B), later compensated by a
rapid growth at the intermediate phase until the matured
stage, could be due to incomplete dependence on the pyru-
vate decarboxylase pathway because of ICL1 allele partial
expression; the glyoxylate pathway is preferred to other
alternative pathways until the depletion of the precursor.
The significant growth of biofilms on RPMI 1640 medium
suggests that ICL does not affect their formation. A possi-
ble rationale is that growth on lactate may enhance C. al-
bicans survival and metabolic activity, influencing biofilm
growth through combinatorial synthesis of limited car-
bon. This supports that multiple assimilation mechanisms
are used simultaneously to maintain their signature resis-
tance (27). Metabolic robustness supports growth, thereby
promoting resistance, which increases with maturation
and metabolic activity.
The resistance phenotype expressed at each formation
stage increased with maturation. The evidence showcased
the insignificant role of ICL in the resistance of sessile
cells, although it may be partially involved in the early-
phase metabolic shift, as shown in Figure 3. However, there
was no significant association between isocitrate lyase and
clinical resistance, signifying that ICL is not a sole deter-
minant of this characteristic. The C. albicans biofilm re-
sistance phenotype signature and virulence potential for
initiating infections was not impaired; in fact, it was en-
hanced by the high metabolic action that increased with
time. Absence of ICL may activate and deactivate other
genes that function in resistance acquisition, as observed
in zap1/zap1 mutants (28). For that reason, a conclusion was
reached that ICL deletion may upregulate other resistance
mechanisms that compensate for its unavailability. Devel-
opmental images define the complexity of biofilms and
identify three distinct growth phases. Filamentous growth
is a prominent feature of biofilms, and hyphae growth in-
capacitation in the absence of ICL to a substantial extent
suggests that there is lower proliferation in tissues and
less establishment of infections through the dissemina-
tion of yeast cells. Furthermore, attenuation of filamen-
tous growth confirms ICL as a promoter of hyphae mor-
phogenesis (24, 26, 29, 30).
The roles of modifying proteins Bgl2, Phr1, and Xog1
have been recently reported to mediate glucan delivery to
the matrix through a controlled channel from the cell wall,
along with depletion signaling. Our results showed the ac-
tivity of the glucan synthase pathway and of β-1, 3-glucan
in the ECM, depicting the activity of delivery mechanisms
(30). Lower accumulation at the early phase may be due
to high energy consumption by the survival and replica-
tion processes. At the mature phases, the significant am-
plification may perhaps be attributed to energy conserva-
tion and upregulation of mechanisms that mediate sur-
vival. It could also be a reflection of stableβ-1, 3-glucan due
to lower sequestration activity as a result of other stage-
specific mechanisms of resistance. Gene expression profil-
ing revealed a substantial effect of ICL on the mRNA of the
resistance genes, suggesting that resistivity tends toward
genotypic variation.
Glucan synthase-encasing gene expression explains
the continual synthesis of β-1, 3-glucan as observed in the
constructed mutants. Previous works have shown that
ERG11 transcripts are higher in young biofilms, which was
supported by the findings of this study (31, 32). Upregu-
lation of ERG11 at the early and intermediate stages sug-
gests that its role is streamlined to certain stages, and its
expression indicates a response to fluconazole treatment
through sterol accumulation and mutation. High ERG11 ex-
pression in ICL1/icl1 suggests that ICL is needed for ERG11
functionality. However, resistance was maintained, sug-
gestive of influences by other mechanisms. The role of
eﬄux-pump genes has been addressed (31, 33, 34). These
genes are responsible for the expulsion of drugs from cells.
The results of the present study revealed the function of
CDR2 to be early-phase-specific. Nevertheless, resistance
was exhibited at all stages, suggestive of other genetic in-
fluences that are yet to be identified. Thus, ICL may be a
part of the synergistic interactions and mechanisms that
mediate biofilm resistance phenotypes.
Biofilm formation by C. albicans ICL heterozygous and
homozygous mutants was found to not be regulated by
ICL, as metabolic activity remained high, suggesting that
ICL is a negative regulator for other synthesizing enzymes
12 Jundishapur J Microbiol. 2016; 9(9):e38031.
Ishola OA et al.
and pathways, thereby advancing the cell’s growth and
homeostasis. The resistance phenotype was expressed at
each formation stage, increasing with maturation. True hy-
phae morphogenesis impairment indicates filamentous
growth as a prominent feature of biofilms, regulated by
the preferred non-fermentable carbohydrate-absorption
pathway.
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